Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy: a Multicenter Randomized Double-blind Placebo-controlled Phase III Trial.
Phase of Trial: Phase III
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Orteronel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 16 May 2019 Last checked against European Clinical Trials Database record.
- 31 Aug 2018 Biomarkers information updated
- 02 Sep 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History